<DOC>
	<DOCNO>NCT02858401</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability 6-dose regimen vesatolimod ( formerly GS-9620 ) ( 1 mg , 2 mg , 4 mg dose level ) HIV-1 infect virologically suppress adult antiretroviral therapy ( ART ) evaluate virologic effect vesatolimod measure change plasma HIV-1 RNA .</brief_summary>
	<brief_title>Safety Biological Activity Vesatolimod HIV-1 Infected , Virologically Suppressed Adults</brief_title>
	<detailed_description />
	<criteria>Key HIV1 infection Aged ≥ 18 year Prebaseline/Day 13 On antiretroviral ( ARV ) treatment ≥ 12 consecutive month prior PreBaseline/Day 13 The following agent allow part current ARV regimen : NRTIs , raltegravir , dolutegravir , rilpivirine , maraviroc The follow agent NOT allow part current ARV regimen : HIV protease inhibitor ( include low dose ritonavir ) , cobicistatcontaining regimen , elvitegravir , efavirenz , etravirine , nevirapine A change ARV regimen ≥ 60 day prior baseline/Day 1 reason virologic failure ( eg , tolerability , simplification , drugdrug interaction profile ) allow Plasma HIV1 RNA &lt; 50 copies/mL screening Documented plasma HIV1 RNA level &lt; 50 copies/mL ( accord local assay use ) ≥ 12 month precede screen visit ( measure least twice use license assay low limit quantitation least 40 copies/mL ) Unconfirmed virologic elevation ≥ 50 copies/mL ( transient detectable viremia , `` blip '' ) prior screen acceptable . ( If low limit detection local HIV1 RNA assay &lt; 50 copies/mL , plasma HIV1 RNA level exceed 50 copies/mL two consecutive HIV1 RNA test ) If ART regimen change ≥ 60 day prior PreBaseline/Day 13 , plasma HIV1 RNA &lt; 50 copies/mL Prebaseline/Day 13 visit require . No documented history resistance component current ARV regimen Availability fully active alternative ARV regimen , opinion Investigator , event discontinuation current ARV regimen development resistance . Hgb ≥ 11.5 g/dL ( male ) ≥ 11 g/dL ( female ) White blood cell ( WBC ) ≥ 2,500 cells/μL Platelets ≥ 125,000/mL Absolute neutrophil count ( ANC ) ≥ 1000 cells/μL CD4 count ≥ 300 cells/μL Albumin ≥ 3.9 g/dL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2 × upper limit normal range ( ULN ) Estimated glomerular filtration rate ≥ 60 mL/min No autoimmune disease Key Hepatitis B surface antigen ( HBsAg ) positive Positive antiHBs antibody negative HBsAg result acceptable Hepatitis C antibody ( HCVAb ) positive Positive antiHCV antibody negative HCV polymerase chain reaction ( PCR ) result acceptable Documented history preART CD4 nadir &lt; 100 cells/µL Unknown preART CD4 nadir acceptable A new AIDSdefining condition diagnose within 90 day prior screen Acute febrile illness within 35 day prior prebaseline/Day 13 Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>